Kilos Return Fast After Stopping Weight-Loss Drugs: Study
New research shows patients quickly regain weight after ending GLP-1 medications like Wegovy. Experts stress the need for long-term lifestyle strategies. Learn the findings.
Category : Pharmaceuticals
Ozempic price drop in Quebec after patent expiry
Generic versions of weight-loss drug Ozempic could slash costs from $400 to under $100 per month in Quebec following a key patent expiration, potentially increasing access for hundreds of thousands.
Canadian Platform to Offer India-Sourced Ozempic to US
A Canadian pharmacy platform plans to supply US patients with Ozempic sourced from India starting in 2026, creating a new cross-border pharmaceutical channel. Learn the details and implications.
Novo Nordisk Plans Lower-Price Ozempic to Fight Generics
Pharmaceutical giant Novo Nordisk is considering a strategic rebrand of a lower-price version of Ozempic to compete directly with upcoming generic alternatives. Learn about the potential market shift.
Wegovy weight-loss pill launches in U.S. as oral alternative
Novo Nordisk launches Wegovy pill in the U.S., providing a flexible, needle-free option for weight management. Learn about this new alternative to injectable medications.
Doctor on Generic Ozempic: 'Exciting Time for Canada'
Dr. Sue Pedersen advises patients to consult their doctors individually about using generic or brand-name Ozempic. A pivotal moment for diabetes and weight-loss treatment access in Canada.
Generic Ozempic Production Approved in Canada, Supply Delayed
Canadian companies can begin producing generic versions of Ozempic starting next week, but experts warn patients should not expect immediate access due to manufacturing and distribution timelines.
Consumer-Driven Future of GLP-1s: Apps & Social Media
Explore how social media trends and digital health apps are transforming access to GLP-1 medications in Canada, moving beyond traditional healthcare channels.
First Postpartum Depression Drug Approved in Canada
Health Canada has approved ZURZUVAE, the first drug specifically for moderate to severe postpartum depression, offering new hope for one in five Canadian mothers. Learn about the treatment and its impact.
Novo Nordisk shares jump 8% on U.S. Wegovy pill approval
Shares of Novo Nordisk surged nearly 8% after the U.S. FDA approved its Wegovy weight-loss pill. The landmark decision marks a major expansion for the obesity drug market.
U.S. Approves Pill Version of Popular Weight-Loss Drug
U.S. regulators have greenlit a pill version of a leading weight-loss medication, potentially broadening treatment options. Learn about the approval and its implications.
FDA Approves Wegovy Weight Loss Pill
U.S. regulators have approved the Wegovy pill for weight loss, a major development in pharmaceutical treatment. Learn about the details and potential impact of this new drug.
B.C. reviews funding for costly cholesterol drug alternative
B.C. is deciding whether to fund Leqvio, a $9,000-per-year drug for genetic high cholesterol patients intolerant to statins. The decision follows new national recommendations.
Sai Life Sciences Releases 2024-25 Sustainability Report
Indian CRDMO leader Sai Life Sciences publishes its latest sustainability report, detailing progress on climate action, renewable energy, and community impact. Read the full findings.
Lilly pill keeps weight off after injectable drugs in trial
New data shows Eli Lilly's oral weight-loss drug successfully maintains weight reduction after patients switch from injectable medications. A breakthrough for chronic obesity management.
Moderna gets $54.3M funding for bird flu vaccine
Moderna secures major funding to develop a bird flu vaccine, highlighting a global push to prepare for potential pandemics. Read about the coalition's investment.
Chronic pain patients face medication shortages in Canada
Canadians with chronic pain describe the daily struggle of navigating nationwide shortages of essential pain control medications. Learn about the personal impact and ongoing supply issues.
Quebec Pharmacist Powers Expansion Slow to Roll Out
The expansion of Quebec pharmacists' prescribing powers, announced to improve healthcare access, is experiencing significant implementation delays. Learn about the causes and impacts.
Pfizer 2026 profit forecast below expectations
Pfizer projects 2026 profits below Wall Street estimates due to a steep drop in COVID product sales and loss of exclusivity for key drugs. Get the full business analysis.
Fake Viagra, Cialis pills seized in Toronto store
Health Canada has seized counterfeit erectile dysfunction medications from a Toronto convenience store. Learn the risks and how to protect yourself from dangerous fake drugs.
Hims & Hers Acquires Livewell for Canadian Expansion
U.S. telehealth giant Hims & Hers acquires Canadian platform Livewell, positioning itself to launch generic semaglutide (Ozempic) in Canada as Novo Nordisk's patent lapses. The move targets a market where two-thirds of adults face weight-related health ch
Eli Lilly cuts price of obesity drug Zepbound
Pharmaceutical giant Eli Lilly has reduced the price of its obesity medication Zepbound to improve patient access. The move comes amid growing demand for GLP-1 drugs in Canada and globally.
FDA Links Child Deaths to COVID Vaccine, Plans Changes
An FDA official's internal memo reveals at least 10 child deaths linked to COVID-19 vaccines, prompting proposed vaccine policy reforms and stricter authorization requirements.
Boehringer Ingelheim Names New Board Member for IT
Boehringer Ingelheim announces Harsha Deshmukh's appointment to Board of Managing Directors for IT and Global Business Services effective February 2026.
SKYRIZI® Gets Positive Reimbursement for UC in Canada
Canada's Drug Agency recommends SKYRIZI® for ulcerative colitis reimbursement, and AbbVie signs a Letter of Intent with the pCPA, improving access for 120,000 Canadians.
Grey Bruce drug disposal nets meds for hockey tickets
Grey Bruce residents exchanged unused pharmaceuticals for Barrie Colts hockey tickets in a successful medication safety initiative. Learn how this program helps combat opioid misuse and environmental contamination.
Dipharma's Novel Method Detects Nitrosamine Risks
Dipharma publishes a peer-reviewed study unveiling a novel method to detect and characterize nitrosamine impurities in Active Pharmaceutical Ingredients, enhancing drug safety and regulatory compliance.
Novo's obesity drug shows 14.5% weight loss in trial
Novo Nordisk's experimental obesity drug amycretin demonstrates significant weight loss results in mid-stage study, advancing to late-phase testing for diabetes patients.
Health Minister noncommittal on pharmacare report
Health Minister Marjorie Michel states the expert pharmacare report is not binding, leaving the future of a national drug plan uncertain. Learn about the implications.
Novo Nordisk Alzheimer's Drug Trials Fail
Danish pharmaceutical giant Novo Nordisk faces major setback as Alzheimer's drug trials fail. Learn how this impacts the weight-loss leader's expansion plans.
Page 2 of 3